CA2316052A1 - Formules de peptides hydrosolubles a liberation continue - Google Patents

Formules de peptides hydrosolubles a liberation continue Download PDF

Info

Publication number
CA2316052A1
CA2316052A1 CA002316052A CA2316052A CA2316052A1 CA 2316052 A1 CA2316052 A1 CA 2316052A1 CA 002316052 A CA002316052 A CA 002316052A CA 2316052 A CA2316052 A CA 2316052A CA 2316052 A1 CA2316052 A1 CA 2316052A1
Authority
CA
Canada
Prior art keywords
sustained release
water soluble
release formulations
soluble peptides
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002316052A
Other languages
English (en)
Other versions
CA2316052C (fr
Inventor
David Bodmer
Jones W. Fong
Thomas Kissel
Hawkins V. Maulding
Oskar Nagele
Jane E. Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002535463A priority Critical patent/CA2535463A1/fr
Priority claimed from CA002020477A external-priority patent/CA2020477C/fr
Publication of CA2316052A1 publication Critical patent/CA2316052A1/fr
Application granted granted Critical
Publication of CA2316052C publication Critical patent/CA2316052C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002316052A 1989-07-07 1990-07-05 Formules de peptides hydrosolubles a liberation continue Expired - Lifetime CA2316052C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002535463A CA2535463A1 (fr) 1989-07-07 1990-07-05 Octreotide-pamoate et son utilisation dans des formulations de peptides hydrosolubles a liberation prolongee

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37702389A 1989-07-07 1989-07-07
US377,023 1989-07-07
US41134789A 1989-09-22 1989-09-22
US411,347 1989-09-22
CA002020477A CA2020477C (fr) 1989-07-07 1990-07-05 Formules de peptides hydrosolubles a liberation continue

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002020477A Division CA2020477C (fr) 1989-07-07 1990-07-05 Formules de peptides hydrosolubles a liberation continue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002535463A Division CA2535463A1 (fr) 1989-07-07 1990-07-05 Octreotide-pamoate et son utilisation dans des formulations de peptides hydrosolubles a liberation prolongee

Publications (2)

Publication Number Publication Date
CA2316052A1 true CA2316052A1 (fr) 1991-01-08
CA2316052C CA2316052C (fr) 2008-09-02

Family

ID=27168773

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002316052A Expired - Lifetime CA2316052C (fr) 1989-07-07 1990-07-05 Formules de peptides hydrosolubles a liberation continue

Country Status (1)

Country Link
CA (1) CA2316052C (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008142153A1 (fr) * 2007-05-24 2008-11-27 Novartis Ag Composition à libération modifiée comprenant un dérivé de somatostatine en microparticules
US8999390B2 (en) 2008-01-30 2015-04-07 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
EP3242318A1 (fr) * 2003-12-19 2017-11-08 The University of North Carolina at Chapel Hill Produit monodispersé de microstructure ou de nanostructure
CN111514118A (zh) * 2020-05-06 2020-08-11 南京林业大学 一种葡萄糖改性的聚乳酸立构复合物载药微球制备方法及产品

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242318A1 (fr) * 2003-12-19 2017-11-08 The University of North Carolina at Chapel Hill Produit monodispersé de microstructure ou de nanostructure
US10842748B2 (en) 2003-12-19 2020-11-24 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- or nano-structures using soft or imprint lithography
US11642313B2 (en) 2003-12-19 2023-05-09 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- or nano-structures using soft or imprint lithography
WO2008142153A1 (fr) * 2007-05-24 2008-11-27 Novartis Ag Composition à libération modifiée comprenant un dérivé de somatostatine en microparticules
US9351923B2 (en) 2007-05-24 2016-05-31 Novartis Ag Extended-release composition comprising a somatostatin derivative in microparticles
EP3666263A1 (fr) * 2007-05-24 2020-06-17 Recordati AG Une composition à libération controlée qui contient une dérivé de somatostatine dans les microparticules
US8999390B2 (en) 2008-01-30 2015-04-07 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
CN111514118A (zh) * 2020-05-06 2020-08-11 南京林业大学 一种葡萄糖改性的聚乳酸立构复合物载药微球制备方法及产品

Also Published As

Publication number Publication date
CA2316052C (fr) 2008-09-02

Similar Documents

Publication Publication Date Title
MY106722A (en) Sustained release formulations of water soluble peptides.
FI870155A0 (fi) Menetelmä ksantaanikumia sisältävän, kiinteän lääkevalmisteen valmistamiseksi
CA2207078A1 (fr) Derives de l'insuline fixant davantage de zinc
WO1995013297A3 (fr) Compositions immunogenes ameliorees agissant contre la gastrine humaine 17
EP0332222A3 (fr) Delivrance intravaginale des polypeptides biologiquement activs
PH30995A (en) Sustained release formulations of water soluble peptides.
HUP0000737A2 (hu) Hialuronsav mikrorészecskékbe foglalt hatóanyagokat tartalmazó nyújtott hatóanyagleadású készítmény
UA35569C2 (uk) Композиція для пролонгованого і контрольованого вивільнення пептидної лікарської речовини і спосіб її одержання, спосіб приготування суспензії, що призначена для парентерального введення
AU624494B2 (en) A method of preparing a freeze-dried formulation containing a drug
CA2128199A1 (fr) Compositions pharmaceutiques, solides, stables, renfermant du maleate d'enalapril
HK1029124A1 (en) Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them.
RU94005001A (ru) Лиофилизат на основе пептида
EP0211601A3 (fr) Stabilisation d'hormones de croissance
CA2316052A1 (fr) Formules de peptides hydrosolubles a liberation continue
CA2356959A1 (fr) Systeme de distribution de medicament insoluble dans l'eau
EP0369474A3 (fr) Composition pharmaceutique pour le traitement de l'oedème cérébral
WO1988003150A3 (fr) Preparations aminoacides contenant des peptides de n,n'-bis-l-aminoacide-l-cystine et destinees a l'administration orale et parenterale
FI991120A (fi) Vesiliukoisten peptidien pitkäaikaisesti vapautuvat koostumukset
ZA9710254B (en) LH-RH peptide analogues, their uses and pharmaceutical composition containing them.
CA2239313A1 (fr) Compose solide, sa preparation et son utilisation en medecine
ES2049617A1 (es) Procedimiento de preparacion de una composicion farmaceutica.
CA2021923A1 (fr) Compose pharmaceutique contenant un derive d'hydantoine
CA2036657A1 (fr) Synthese d'analogues de lh-rh assurant une protection minimale temporaire
RU97120940A (ru) Пептид, обладающий иммуномодулирующей активностью, и препарат на его основе
RU96111534A (ru) Пищевая биологически активная добавка тинростим-с

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry